Shengqiang Yu

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Targeting the stromal androgen receptor in primary prostate tumors at earlier stages

Yuanjie Niu, Saleh Altuwaijri, Shuyuan Yeh et al. · Proceedings of the National Academy of Sciences · 2008 · 143 citations · Full text

Medicine, Oncology, Urology +17

Androgen Receptor Is a Potential Therapeutic Target for Bladder Cancer

Jitao Wu, Bangmin Han, Shengqiang Yu et al. · Urology · 2010 · 87 citations

Medicine, Oncology, Urology +15

Androgen receptor in human prostate cancer-associated fibroblasts promotes prostate cancer epithelial cell growth and invasion

Shengqiang Yu, Shujie Xia, Diandong Yang et al. · Medical Oncology · 2013 · 87 citations

Medicine, Oncology, Urology +16

Defects of Prostate Development and Reproductive System in the Estrogen Receptor-α Null Male Mice

Ming Chen, Iawen Hsu, Andrew Wolfe et al. · Endocrinology · 2008 · 84 citations · Full text

Medicine, Endocrinology, Physiology +17